<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04817644</url>
  </required_header>
  <id_info>
    <org_study_id>NN9924-4669</org_study_id>
    <secondary_id>U1111-1253-4467</secondary_id>
    <nct_id>NCT04817644</nct_id>
  </id_info>
  <brief_title>A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets</brief_title>
  <official_title>A Trial Investigating Semaglutide and SNAC Concentrations in Breastmilk Following Administration of Multiple Doses of Oral Semaglutide in Healthy, Lactating Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants in the study, will receive the study drug once daily for 10 days in tablet form&#xD;
      for oral (by mouth) intake. On day 1 to 5 the tablet will contain 3 mg semaglutide, and on&#xD;
      day 6-10 the tablet will contain 7 mg semaglutide.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the semaglutide milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>nmol*h/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the salcaprozate sodium (SNAC) milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,SNAC,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng*h/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average semaglutide milk concentration during a dosing interval after the 10th dosing (Cavg,sema,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum semaglutide milk concentration during a dosing interval after the 10th dosing (Cmax,sema,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum semaglutide milk concentration during a dosing interval after the 10th dosing (Cmin,sema,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum semaglutide milk concentration during a dosing interval after the 10th dosing (tmax,sema,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>Hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated daily infant semaglutide dose</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>mg/kg/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative daily infant semaglutide dose</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average SNAC milk concentration during a dosing interval after the 10th dosing (Cavg,SNAC,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum SNAC milk concentration during a dosing interval after the 10th dosing (Cmax,SNAC,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum SNAC milk concentration during a dosing interval after the 10th dosing (Cmin,SNAC,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum SNAC milk concentration during a dosing interval after the 10th dosing (tmax,SNAC,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated daily infant SNAC dose</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/kg/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative daily infant SNAC dose</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the SNAC metabolite E494 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E494,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng*h/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cavg,E494,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cmax,E494,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cmin,E494,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum SNAC metabolite E494 milk concentration after the 10th dosing (tmax,E494,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated daily infant SNAC metabolite E494 dose</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/kg/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the SNAC metabolite E506 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E506,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng*h/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cavg,E506,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cmax,E506,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cmin,E506,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum SNAC metabolite E506 milk concentration after the 10th dosing (tmax,E506,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated daily infant SNAC metabolite E506 dose</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/kg/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the SNAC metabolite E1245 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1245,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng*h/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cavg,E1245,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cmax,E1245,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cmin,E1245,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum SNAC metabolite E1245 milk concentration after the 10th dosing (tmax,E1245,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated daily infant SNAC metabolite E1245 dose</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/kg/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the SNAC metabolite E1246 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1246,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng*h/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cavg,E1246,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cmax,E1246,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cmin,E1246,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum SNAC metabolite E1246 milk concentration in milk after the 10th dosing (tmax,E1246,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated daily infant SNAC metabolite E1246 dose</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/kg/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the SNAC metabolite E1247 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1247,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng*h/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cavg,E1247,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cmax,E1247,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cmin,E1247,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum SNAC metabolite E1247 milk concentration after the 10th dosing (tmax,E1247,D10,milk)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated daily infant SNAC metabolite E1247 dose</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/kg/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the semaglutide plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>nmol*h/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum semaglutide plasma concentration during a dosing interval after the 10th dosing (Cmax,sema,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum semaglutide plasma concentration during a dosing interval after the 10th dosing (tmax,sema,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the SNAC plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,SNAC,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng*h/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum SNAC plasma concentration during a dosing interval after the 10th dosing (Cmax,SNAC,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum SNAC plasma concentration during a dosing interval after the 10th dosing (tmax,SNAC,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the SNAC metabolite E494 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E494,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng*h/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum SNAC metabolite E494 plasma concentration during a dosing interval after the 10th dosing (Cmax,E494,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum SNAC metabolite E494 plasma concentration during a dosing interval after the 10th dosing (tmax,E494,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the SNAC metabolite E506 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E506,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng*h/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum SNAC metabolite E506 plasma concentration during a dosing interval after the 10th dosing (Cmax,E506,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum SNAC metabolite E506 plasma concentration during a dosing interval after the 10th dosing (tmax,E506,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the SNAC metabolite E1245 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1245,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng*h/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum SNAC metabolite E1245 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1245,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum SNAC metabolite E1245 plasma concentration during a dosing interval after the 10th dosing (tmax,E1245,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the SNAC metabolite E1246 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1246,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng*h/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum SNAC metabolite E1246 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1246,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum SNAC metabolite E1246 plasma concentration during a dosing interval after the 10th dosing (tmax,E1246,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the SNAC metabolite E1247 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1247,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng*h/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum SNAC metabolite E1247 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1247,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum SNAC metabolite E1247 plasma concentration during a dosing interval after the 10th dosing (tmax,E1247,D10,plasma)</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing (day 10)</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Oral semaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive oral semaglutide once daily for a total of 10 days: 3 mg for 5 days followed by 7 mg for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral semaglutide</intervention_name>
    <description>Oral semaglutide once daily for a total of 10 days</description>
    <arm_group_label>Oral semaglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, female subjects who have given birth at least 3 months prior to screening and&#xD;
             who breastfeed (breastfeeding is defined by feeding the baby milk produced by the&#xD;
             mother. Using a breast pump to collect milk and subsequently feeding it to the baby by&#xD;
             bottle, is also defined as breastfeeding ) their infant to an extent, where the&#xD;
             majority of the infant's total energy intake is from breastfeeding and sufficient milk&#xD;
             is produced to fulfil the trial requirements, as judged by the investigator.&#xD;
&#xD;
          -  Agree to abstain from breastfeeding their infant from first dose of oral semaglutide&#xD;
             to the &quot;End of trial&quot; visit (total of 47 days) to avoid potentially exposing their&#xD;
             child to semaglutide and SNAC.&#xD;
&#xD;
          -  The breastfed infant is able to feed from a bottle (expenses related to alternative&#xD;
             infant nutrition during trial participation will be covered by Novo Nordisk) prior to&#xD;
             screening.&#xD;
&#xD;
          -  Age above or equal to 18 years at the time of signing informed consent.&#xD;
&#xD;
          -  Body mass index (BMI) between 20.0 and 32.4 kg/m^2 (both inclusive).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female who is pregnant or intends to become pregnant or is of child-bearing potential&#xD;
             and not using an effective contraceptive method.&#xD;
&#xD;
          -  Glycated haemoglobin (HbA1c) greater than or equal to 6.5 % (48 mmol/mol) at&#xD;
             screening.&#xD;
&#xD;
          -  Presence of clinically significant gastrointestinal disorders or symptoms of&#xD;
             gastrointestinal disorders potentially affecting absorption of drugs or nutrients, as&#xD;
             judged by the investigator.&#xD;
&#xD;
          -  History (as declared by the subject or reported in the medical records) of major&#xD;
             surgical procedures involving the stomach potentially affecting absorption of trial&#xD;
             products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass&#xD;
             surgery).&#xD;
&#xD;
          -  Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or&#xD;
             medullary thyroid carcinoma (as declared by the subject or reported in the medical&#xD;
             records).&#xD;
&#xD;
          -  Presence or history (as declared by the subject or reported in the medical records) of&#xD;
             malignant neoplasm within 5 years prior to the day of screening (basal or squamous&#xD;
             cell skin cancer, or any carcinoma in-situ is allowed).&#xD;
&#xD;
          -  Presence or history (as declared by the subject or reported in the medical records) of&#xD;
             pancreatitis (acute or chronic).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (dept. 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

